EP0563239A4 - Gene recepteur tronque d'interleukine-1 utilise pour le traitement de l'arthrite. - Google Patents

Gene recepteur tronque d'interleukine-1 utilise pour le traitement de l'arthrite.

Info

Publication number
EP0563239A4
EP0563239A4 EP19920902630 EP92902630A EP0563239A4 EP 0563239 A4 EP0563239 A4 EP 0563239A4 EP 19920902630 EP19920902630 EP 19920902630 EP 92902630 A EP92902630 A EP 92902630A EP 0563239 A4 EP0563239 A4 EP 0563239A4
Authority
EP
European Patent Office
Prior art keywords
interceukin
arthritis
trunk
treatment
receptor gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19920902630
Other languages
German (de)
English (en)
Other versions
EP0563239A1 (fr
Inventor
Joseph C Glorioso
Christopher H Evans
Paul D Robbins
Geethani Bandara
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pittsburgh
Original Assignee
University of Pittsburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pittsburgh filed Critical University of Pittsburgh
Publication of EP0563239A1 publication Critical patent/EP0563239A1/fr
Publication of EP0563239A4 publication Critical patent/EP0563239A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13045—Special targeting system for viral vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP19920902630 1990-12-20 1991-12-09 Gene recepteur tronque d'interleukine-1 utilise pour le traitement de l'arthrite. Withdrawn EP0563239A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63098190A 1990-12-20 1990-12-20
US630981 1990-12-20
PCT/US1991/009231 WO1992011359A1 (fr) 1990-12-20 1991-12-09 Gene recepteur tronque d'interleukine-1 utilise pour le traitement de l'arthrite

Publications (2)

Publication Number Publication Date
EP0563239A1 EP0563239A1 (fr) 1993-10-06
EP0563239A4 true EP0563239A4 (fr) 1994-10-12

Family

ID=24529337

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19920902630 Withdrawn EP0563239A4 (fr) 1990-12-20 1991-12-09 Gene recepteur tronque d'interleukine-1 utilise pour le traitement de l'arthrite.

Country Status (4)

Country Link
EP (1) EP0563239A4 (fr)
JP (1) JPH06504440A (fr)
CA (1) CA2098848A1 (fr)
WO (1) WO1992011359A1 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6159464A (en) * 1990-12-20 2000-12-12 University Of Pittsburgh Of The Commonwealth System Of Higher Education Viral vectors to inhibit leukocyte infiltration or cartilage degradation of joints
US6156304A (en) * 1990-12-20 2000-12-05 University Of Pittsburgh Of The Commonwealth System Of Higher Education Gene transfer for studying and treating a connective tissue of a mammalian host
US6228356B1 (en) 1990-12-20 2001-05-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Viral vectors to inhibit leukocyte infiltration or cartilage degradation of joints
US5858355A (en) * 1990-12-20 1999-01-12 University Of Pittsburgh Of The Commonwealth System Of Higher Education IRAP gene as treatment for arthritis
US6413511B1 (en) * 1990-12-20 2002-07-02 University Of Pittsburgh Of The Commonwealth System Of Higher Education Cartilage alterations by administering to joints chondrocytes comprising a heterologous polynucleotide
US5792751A (en) * 1992-04-13 1998-08-11 Baylor College Of Medicine Tranformation of cells associated with fluid spaces
EP0653943A4 (fr) * 1992-07-13 1996-10-02 Baylor College Medicine Ciblage d'une therapie genique somatique en direction des articulations.
JPH08511507A (ja) * 1993-03-08 1996-12-03 ユニバーシティー オブ ピッツバーグ オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション 哺乳動物宿主の結合組織を処置するための遺伝子導入
US5645829A (en) * 1993-06-18 1997-07-08 Beth Israel Hospital Association Mesothelial cell gene therapy
AU7516594A (en) * 1993-07-28 1995-02-28 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Pre-binding of retroviral vector particles with complement components to enable the performance of human gene therapy (in vivo)
EP0690673A4 (fr) * 1993-12-14 1996-05-29 Univ Pittsburgh Traitement systemique par genes des affections des tissus conjonctifs
JPH083058A (ja) * 1994-06-17 1996-01-09 Hoechst Japan Ltd 新規な骨代謝疾患治療剤
PT807183E (pt) * 1994-08-26 2001-05-31 Aventis Pharma Gmbh Terapia genetica de doencas induzidas pelo sistema imunitario com auxilio de uma substancia reguladora do ciclo celular especifica das celulas
US6096728A (en) * 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases
US6294170B1 (en) 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
JP2001514235A (ja) * 1997-09-02 2001-09-11 カイロン コーポレイション 遺伝子治療を利用して関節炎を処置するための組成物および方法
EP1939300A1 (fr) 1999-05-28 2008-07-02 Targeted Genetics Corporation Procédés et compositions pour diminuer le niveau de facteur de nécrose de tumeur (TNF) pour des troubles associés au TNF
EP1180159B1 (fr) 1999-05-28 2008-09-03 Targeted Genetics Corporation Techniques et compositions permettant d'abaisser le niveau de facteur de necrose tumorale (tnf) dans les troubles associes au tnf
WO2001013960A1 (fr) * 1999-08-20 2001-03-01 University Of Pittsburgh Of The Commonwealth System Of Higher Education Procedes d'administration de genes in vivo a des sites de deterioration de cartilage
AU2002311777A1 (en) * 2001-04-17 2002-10-28 Genetix Pharmaceuticals, Inc. Method of treating arthritis using lentiviral vectors in gene therapy
JP2007531738A (ja) 2004-04-02 2007-11-08 アムジエン・インコーポレーテツド ＩＬ−１ｒａの凝集を低下させる方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0318296A2 (fr) * 1987-11-25 1989-05-31 Immunex Corporation Récepteurs d'interleukine-1
WO1989004838A1 (fr) * 1987-11-25 1989-06-01 Immunex Corporation Recepteurs d'interleukine-1

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0318296A2 (fr) * 1987-11-25 1989-05-31 Immunex Corporation Récepteurs d'interleukine-1
WO1989004838A1 (fr) * 1987-11-25 1989-06-01 Immunex Corporation Recepteurs d'interleukine-1

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
M. ROBERTSON: "Gene therapy. Desperate appliances.", NATURE, vol. 320, 20 March 1986 (1986-03-20), LONDON, GB, pages 213 - 214 *
M. TSUDA ET AL.: "Retrovirus-mediated gene transfer into mouse cerebellar primary culture and its application to the neural transplantation.", BRAIN RESEARCH BULLETIN, vol. 24, no. 6, 1990, pages 787 - 792 *
P. ROUX ET AL.: "A versatile and potentially general approach to the targeting of specific cell types by retroviruses: Application to the infection of human cells by means of major histocompatibility complex class I and class II antigens by mouse ecotropic murine leukemia virus-derived viruses.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE USA, vol. 86, no. 23, December 1989 (1989-12-01), WASHINGTON, DC, USA, pages 9079 - 9083 *
See also references of WO9211359A1 *
T. FRIEDMANN: "Progress toward human gene therapy.", SCIENCE, vol. 244, no. 4910, 16 June 1989 (1989-06-16), WASHINGTON, DC, USA, pages 1275 - 1281 *

Also Published As

Publication number Publication date
CA2098848A1 (fr) 1992-06-21
JPH06504440A (ja) 1994-05-26
WO1992011359A1 (fr) 1992-07-09
EP0563239A1 (fr) 1993-10-06

Similar Documents

Publication Publication Date Title
FR2685206B1 (fr) Dispositif de drainage implantable pour le traitement de l'hydrocephalie.
FR2675597B1 (fr) Unite de traitement d'electrophotographie.
OA09364A (fr) "Composition fongicide pour traitement de semences".
EP0593181A3 (fr) Gaines pour introduction.
FR2663044B1 (fr) Appareil pour le traitement de surfaces.
MA21962A1 (fr) Procede pour la preparation d'inhibiteurs de proteass retrovirales .
OA09117A (fr) Utilisation d'une composition pour le traitement en surface de sols.
EP0601058A4 (fr) Formulations transdermiques pour l'administration de prazosine.
FR2684554B1 (fr) Medicaments pour le traitement d'etats inflammatoires ou pour l'analgesie.
FR2660301B1 (fr) Dispositif pour la production d'ozone.
DZ3014A1 (fr) Médicaments pour le traitement de l'hypertension.
EP0689455A4 (fr) Strategies therapeutiques pour le traitement d'infections virales groupees immuno-infectieuses
FR2695997B1 (fr) Système gyroscopique pour le mesurage d'angles.
EP0657438A3 (fr) Procédé pour la préparation d'alkylesulfinylbenzamides et de 1,2-benzoisothiazol-3-ones.
IT1292552B1 (it) Dispositivo per l'applicazione di rivestimenti.
FR2710267B3 (fr) Composition pour le traitement de l'impuissance masculine.
DZ1988A1 (fr) Thérapie de combinaison pour le traitement de l'hiv.
FR2693129B1 (fr) Outillage pour le traitement électrochimique de la surface interne d'un tube.
DZ2012A1 (fr) Benzamides pour le traitement de dégénérescences neurologiques.
FR2658419B1 (fr) Medicament pour le traitement de la dermatite.
FR2536995B1 (fr) Composition pour le traitement de l'arthrite
FR2660300B1 (fr) Dispositif pour la production d'ozone.
FR2683722B1 (fr) Medicament pour le traitement de fond de l'asthme a base de beta-carotene.
FR2680123B1 (fr) Procede de traitement de residus fortement polluants pour l'environnement.
FR2697436B1 (fr) Assouplisseur d'anneaux réglable pour la gymnastique.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19930715

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE

A4 Supplementary search report drawn up and despatched

Effective date: 19940824

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE

RBV Designated contracting states (corrected)

Designated state(s): CH DE ES FR GB IT LI NL SE

17Q First examination report despatched

Effective date: 19980623

18D Application deemed to be withdrawn

Effective date: 20010911